ESMO Plenary Mar 2022 - ESMO Virtual Plenaries: March 2022
Mar 16 - Mar 18, 2022 | LuganoSwitzerland
LARVOL is not affiliated with ESMO Virtual Plenaries: March 2022 and all trademarks, logos, and brand names are property of their respective owners
Showing 3 abstracts linked to Trials
Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer